Cullinan Therapeutics has filed an investigational new drug application with the U.S. Food and Drug Administration (FDA) for CLN-978 for the treatment of systemic lupus erythematosus (SLE).
In a new study, researchers investigated the prevalence of cardiovascular disease events (CVE) in people with systemic lupus ...
Autoimmune diseases, including systemic lupus erythematosus (SLE), are more common in women than men, and scientists are ...
A recent study found that regularly checking blood levels of hydroxychloroquine (HCQ, known commercially as Plaquenil®) may ...
An ophthalmologist conducted a visual examination which showed central retinal artery occlusion (CRAO), the blockage of a ...
In a recent study, researchers explored the association between HCQ and the overall risk of CV events in people with SLE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback